HLA-B7-restricted EBV-specific CD8 + T cells are dysregulated in multiple sclerosis

Journal of Immunology

Volumn 188, Issue 9, 2012, Pages 4671-4680

  Jilek, Samantha ^a   Schluep, Myriam ^a   Harari, Alexandre ^a,b   Canales, Mathieu ^a   Lysandropoulos, Andreas ^a   Zekeridou, Anastasia ^a   Pantaleo, Giuseppe ^a,b   Du Pasquier, Renaud A ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Swiss Vaccine Research Institute   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; EPITOPE; GRANZYME B; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; HLA B7 ANTIGEN; HLA B8 ANTIGEN; INTERLEUKIN 2; PEPTIDE; PERFORIN; VIRUS PROTEIN;

ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CELL GRANULE; CELL MEDIATED CYTOTOXICITY; CELL SPECIFICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; EX VIVO STUDY; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; VIRUS CELL INTERACTION;

CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HLA-A2 ANTIGEN; HLA-B7 ANTIGEN; HLA-B8 ANTIGEN; HUMANS; MALE; MULTIPLE SCLEROSIS;

EID: 84860330754     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1103100     Document Type: Article

References (56)

1. Ascherio, A., and K. L. Munger. 2007. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann. Neurol. 61: 288-299. (Pubitemid 46676728)
2. Oksenberg, J. R., S. E. Baranzini, S. Sawcer, and S. L. Hauser. 2008. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat. Rev. Genet. 9: 516-526. (Pubitemid 351861542)
3. Fogdell-Hahn, A., A. Ligers, M. Grønning, J. Hillert, and O. Olerup. 2000. Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease. Tissue Antigens 55: 140-148. (Pubitemid 30103439)
4. Zivadinov, R., B. Weinstock-Guttman, M. Zorzon, L. Uxa, M. Serafin, A. Bosco, A. Bratina, C. Maggiore, A. Grop, M. A. Tommasi, et al. 2009. Geneenvironment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis. J. Neuroimmunol. 209: 123-130.
5. DeLorenze, G. N., K. L. Munger, E. T. Lennette, N. Orentreich, J. H. Vogelman, and A. Ascherio. 2006. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch. Neurol. 63: 839-844. (Pubitemid 43882291)
6. Sundström, P., P. Juto, G. Wadell, G. Hallmans, A. Svenningsson, L. Nyström, J. Dillner, and L. Forsgren. 2004. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 62: 2277-2282. (Pubitemid 38787787)
7. Cepok, S., D. Zhou, R. Srivastava, S. Nessler, S. Stei, K. Büssow, N. Sommer, and B. Hemmer. 2005. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J. Clin. Invest. 115: 1352-1360. (Pubitemid 40629055)
8. Höllsberg, P., H. J. Hansen, and S. Haahr. 2003. Altered CD8+ T cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis. Clin. Exp. Immunol. 132: 137-143. (Pubitemid 36418916)
9. Jilek, S., M. Schluep, P. Meylan, F. Vingerhoets, L. Guignard, A. Monney, J. Kleeberg, G. Le Goff, G. Pantaleo, and R. A. Du Pasquier. 2008. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain 131: 1712-1721. (Pubitemid 351957461)
10. Lünemann, J. D., N. Edwards, P. A. Muraro, S. Hayashi, J. I. Cohen, C. Münz, and R. Martin. 2006. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 129: 1493-1506. (Pubitemid 43999382)
11. Jaquiéry, E., S. Jilek, M. Schluep, P. Meylan, A. Lysandropoulos, G. Pantaleo, and R. A. Du Pasquier. 2010. Intrathecal immune responses to EBV in early MS. Eur. J. Immunol. 40: 878-887.
12. Pender, M. P., P. A. Csurhes, A. Lenarczyk, C. M. Pfluger, and S. R. Burrows. 2009. Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 80: 498-505.
13. Lindsey, J. W., L. M. Hatfield, M. P. Crawford, and S. Patel. 2009. Quantitative PCR for Epstein-Barr virus DNA and RNA in multiple sclerosis. Mult. Scler. 15: 153-158.
14. Pender, M. P. 2011. The essential role of Epstein-Barr virus in the pathogenesis of multiple sclerosis. Neuroscientist 17: 351-367.
15. Hoshino, Y., T. Morishima, H. Kimura, K. Nishikawa, T. Tsurumi, and K. Kuzushima. 1999. Antigen-driven expansion and contraction of CD8+-activated T cells in primary EBV infection. J. Immunol. 163: 5735-5740.
16. Jaquiéry, E., S. Jilek, M. Schluep, G. Le Goff, M. Garcia, G. Pantaleo, and R. A. Du Pasquier. 2010. Cytokine mRNA profile of Epstein-Barr virusstimulated highly differentiated T cells in multiple sclerosis: a pilot study. J. Neuroimmunol. 225: 167-170.
17. Harari, A., V. Dutoit, C. Cellerai, P. A. Bart, R. A. Du Pasquier, and G. Pantaleo. 2006. Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol. Rev. 211: 236-254. (Pubitemid 43882976)
18. Cellerai, C., A. Harari, H. Stauss, S. Yerly, A. M. Geretti, A. Carroll, T. Yee, J. Ainsworth, I. Williams, J. Sweeney, et al. 2011. Early and prolonged anti-retroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term non-progressors. PLoS ONE 6: e18164.
19. Cellerai, C., M. Perreau, V. Rozot, F. B. Enders, G. Pantaleo, and A. Harari. 2010. Proliferation capacity and cytotoxic activity are mediated by functionally and phenotypically distinct virus-specific CD8 T cells defined by interleukin-7Ralpha (CD127) and perforin expression. J. Virol. 84: 3868-3878.
20. Zimmerli, S. C., A. Harari, C. Cellerai, F. Vallelian, P. A. Bart, and G. Pantaleo. 2005. HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc. Natl. Acad. Sci. USA 102: 7239-7244. (Pubitemid 40696363)
21. Chowdhury, D., and J. Lieberman. 2008. Death by a thousand cuts: granzyme pathways of programmed cell death. Annu. Rev. Immunol. 26: 389-420. (Pubitemid 351611623)
22. Mintern, J. D., C. Guillonneau, F. R. Carbone, P. C. Doherty, and S. J. Turner. 2007. Cutting edge: Tissue-resident memory CTL down-regulate cytolytic molecule expression following virus clearance. J. Immunol. 179: 7220-7224.
23. Harari, A., F. B. Enders, C. Cellerai, P. A. Bart, and G. Pantaleo. 2009. Distinct profiles of cytotoxic granules in memory CD8 T cells correlate with function, differentiation stage, and antigen exposure. J. Virol. 83: 2862-2871.
24. Yoshimi, A., I. Tsuge, H. Namizaki, Y. Hoshino, H. Kimura, Y. Takahashi, N. Watanabe, K. Kuzushima, and S. Kojima. 2002. Epstein-Barr virus-specific T-cell cytotoxicity is mediated through the perforin pathway in patients with lymphoproliferative disorders after allogeneic bone marrow transplantation. Br. J. Haematol. 116: 710-715. (Pubitemid 34178678)
25. Polman, C. H., S. C. Reingold, G. Edan, M. Filippi, H. P. Hartung, L. Kappos, F. D. Lublin, L. M. Metz, H. F. McFarland, P. W. O'Connor, et al. 2005. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol. 58: 840-846. (Pubitemid 41746873)
26. Brynedal, B., K. Duvefelt, G. Jonasdottir, I. M. Roos, E. Akesson, J. Palmgren, and J. Hillert. 2007. HLA - A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PLoS ONE 2: e664.
27. Harbo, H. F., B. A. Lie, S. Sawcer, E. G. Celius, K. Z. Dai, A. Oturai, J. Hillert, A. R. Lorentzen, M. Laaksonen, K. M. Myhr, et al. 2004. Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. Tissue Antigens 63: 237-247. (Pubitemid 38297258)
28. Gonzalez-Galarza, F. F., S. Christmas, D. Middleton, and A. R. Jones. 2011. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res. 39(Database issue): D913-D919.
29. Jilek, S., E. Jaquiéry, H. H. Hirsch, A. Lysandropoulos, M. Canales, L. Guignard, M. Schluep, G. Pantaleo, and R. A. Du Pasquier. 2010. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol. 9: 264-272.
30. Roederer, M., J. L. Nozzi, and M. C. Nason. 2011. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 79: 167-174.
31. Champagne, P., G. S. Ogg, A. S. King, C. Knabenhans, K. Ellefsen, M. Nobile, V. Appay, G. P. Rizzardi, S. Fleury, M. Lipp, et al. 2001. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410: 106-111. (Pubitemid 32225845)
32. Brenchley, J. M., N. J. Karandikar, M. R. Betts, D. R. Ambrozak, B. J. Hill, L. E. Crotty, J. P. Casazza, J. Kuruppu, S. A. Migueles, M. Connors, et al. 2003. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 101: 2711-2720. (Pubitemid 36857634)
33. Day, C. L., D. E. Kaufmann, P. Kiepiela, J. A. Brown, E. S. Moodley, S. Reddy, E. W. Mackey, J. D. Miller, A. J. Leslie, C. DePierres, et al. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350-354. (Pubitemid 44435155)
34. Chen, G., P. Shankar, C. Lange, H. Valdez, P. R. Skolnik, L. Wu, N. Manjunath, and J. Lieberman. 2001. CD8 T cells specific for human immunodeficiency virus, Epstein-Barr virus, and cytomegalovirus lack molecules for homing to lymphoid sites of infection. Blood 98: 156-164.
35. Jilek, S., M. Schluep, A. O. Rossetti, L. Guignard, G. Le Goff, G. Pantaleo, and R. A. Du Pasquier. 2007. CSF enrichment of highly differentiated CD8+ T cells in early multiple sclerosis. Clin. Immunol. 123: 105-113. (Pubitemid 46401506)
36. Zivadinov, R., L. Uxa, T. Zacchi, D. Nasuelli, M. Ukmar, C. Furlan, R. Pozzi-Mucelli, M. A. Tommasi, L. Locatelli, S. Ulivi, et al. 2003. HLA genotypes and disease severity assessed by magnetic resonance imaging findings in patients with multiple sclerosis. J. Neurol. 250: 1099-1106. (Pubitemid 37152560)
37. Gronen, F., K. Ruprecht, B. Weissbrich, E. Klinker, A. Kroner, H. H. Hofstetter, and P. Rieckmann. 2006. Frequency analysis of HLA-B7-restricted Epstein-Barr virus-specific cytotoxic T lymphocytes in patients with multiple sclerosis and healthy controls. J. Neuroimmunol. 180: 185-192. (Pubitemid 44692331)
38. Cappellano, G., E. Orilieri, C. Comi, A. Chiocchetti, S. Bocca, E. Boggio, I. S. Bernardone, A. Cometa, R. Clementi, N. Barizzone, et al. 2008. Variations of the perforin gene in patients with multiple sclerosis. Genes Immun. 9: 438-444.
39. Hislop, A. D., U. Palendira, A. M. Leese, P. D. Arkwright, P. S. Rohrlich, S. G. Tangye, H. B. Gaspar, A. C. Lankester, A. Moretta, and A. B. Rickinson. 2010. Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets. Blood 116: 3249-3257.
40. Pender, M. P., P. A. Csurhes, C. M. Pfluger, and S. R. Burrows. 2011. Decreased CD8+ T cell response to Epstein-Barr virus infected B cells in multiple sclerosis is not due to decreased HLA class I expression on B cells or monocytes. BMC Neurol. 11: 95.
41. Greenough, T. C., S. C. Campellone, R. Brody, S. Jain, V. Sanchez-Merino, M. Somasundaran, and K. Luzuriaga. 2010. Programmed Death-1 expression on Epstein Barr virus specific CD8+ T cells varies by stage of infection, epitope specificity, and T-cell receptor usage. PLoS ONE 5: e12926.
42. Lichterfeld, M., D. E. Kaufmann, X. G. Yu, S. K. Mui, M. M. Addo, M. N. Johnston, D. Cohen, G. K. Robbins, E. Pae, G. Alter, et al. 2004. Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J. Exp. Med. 200: 701-712. (Pubitemid 39299457)
43. Hautecoeur, P., G. Forzy, P. Gallois, V. Demirbilek, and O. Feugas. 1997. Variations of IL2, IL6, TNF alpha plasmatic levels in relapsing remitting multiple sclerosis. Acta Neurol. Belg. 97: 240-243. (Pubitemid 128523426)
44. Clerici, M., M. Saresella, D. Trabattoni, L. Speciale, S. Fossati, S. Ruzzante, R. Cavaretta, M. Filippi, D. Caputo, and P. Ferrante. 2001. Single-cell analysis of cytokine production shows different immune profiles in multiple sclerosis patients with active or quiescent disease. J. Neuroimmunol. 121: 88-101. (Pubitemid 34008456)
45. Schluep, M., G. van Melle, H. Henry, C. Städler, B. Roth-Wicky, and P. J. Magistretti. 1998. In vitro cytokine profiles as indicators of relapse activity and clinical course in multiple sclerosis. Mult. Scler. 4: 198-202. (Pubitemid 28410051)
46. Vandenbroeck, K. 2011. Cytokine Gene Polymorphisms and Human Autoimmune Disease in the Era of Genome-Wide Association Studies. J. Interferon Cytokine Res. DOI: 10.1089/jir.2011.0103.
47. Hafler, D. A., A. Compston, S. Sawcer, E. S. Lander, M. J. Daly, P. L. De Jager, P. I. de Bakker, S. B. Gabriel, D. B. Mirel, A. J. Ivinson, et al; International Multiple Sclerosis Genetics Consortium. 2007. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 357: 851-862. (Pubitemid 47347319)
48. Maier, L. M., C. E. Lowe, J. Cooper, K. Downes, D. E. Anderson, C. Severson, P. M. Clark, B. Healy, N. Walker, C. Aubin, et al; International Multiple Sclerosis Genetics Consortium. 2009. IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet. 5: e1000322.
49. The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case Control Consortium 2. 2011. Genetic risk and a primary role for cellmediated immune mechanisms in multiple sclerosis. Nature 476: 214-219.
50. Woodberry, T., T. J. Suscovich, L. M. Henry, J. K. Davis, N. Frahm, B. D. Walker, D. T. Scadden, F. Wang, and C. Brander. 2005. Differential targeting and shifts in the immunodominance of Epstein-Barr virus - specific CD8 and CD4 T cell responses during acute and persistent infection. J. Infect. Dis. 192: 1513-1524. (Pubitemid 41504686)
51. *0702-associated epitope derived from an Epstein-Barr virus helicase-primase-associated protein. J. Med. Virol. 72: 635-645. (Pubitemid 38296076)
52. Bharadwaj, M., S. R. Burrows, J. M. Burrows, D. J. Moss, M. Catalina, and R. Khanna. 2001. Longitudinal dynamics of antigen-specific CD8+ cytotoxic T lymphocytes following primary Epstein-Barr virus infection. Blood 98: 2588-2589.
53. Hill, A. B., S. P. Lee, J. S. Haurum, N. Murray, Q. Y. Yao, M. Rowe, N. Signoret, A. B. Rickinson, and A. J. McMichael. 1995. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised. J. Exp. Med. 181: 2221-2228.
54. Bogedain, C., H. Wolf, S. Modrow, G. Stuber, and W. Jilg. 1995. Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus. J. Virol. 69: 4872-4879.
55. *0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 90: 1751-1767. (Pubitemid 27377285)
56. Wills, M. R., A. J. Carmichael, K. Mynard, X. Jin, M. P. Weekes, B. Plachter, and J. G. Sissons. 1996. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J. Virol. 70: 7569-7579. (Pubitemid 26340108)